Akero Total Liab vs Retained Earnings Analysis

AKRO Stock

USD 32.17 1.01 3.24%

Akero Therapeutics financial indicator trend analysis is way more than just evaluating Akero Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Akero Therapeutics is a good investment. Please check the relationship between Akero Therapeutics Total Liab and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

Total Liab vs Retained Earnings

Total Liab vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Akero Therapeutics Total Liab account and Retained Earnings. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Akero Therapeutics' Total Liab and Retained Earnings is -0.3. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Akero Therapeutics, assuming nothing else is changed. The correlation between historical values of Akero Therapeutics' Total Liab and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Akero Therapeutics are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Total Liab i.e., Akero Therapeutics' Total Liab and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.3

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Akero Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Akero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.As of the 28th of November 2024, Enterprise Value is likely to grow to about 1.8 B, while Selling General Administrative is likely to drop about 16.8 M.

Akero Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Capital Surpluse	Non Current Liabilities Other	Short Long Term Debt Total	Property Plant And Equipment Net	Net Receivables	Capital Lease Obligations
Total Assets		0.74	0.79	0.99	0.96	-0.91	-0.98	0.82	0.87	0.89	0.11	0.12	1.0	0.75	0.08	0.81	0.28	0.99	1.0	1.0	0.88	0.33	0.91	-0.93	0.79	-0.91
Other Current Liab	0.74		0.99	0.74	0.81	-0.87	-0.81	0.89	0.87	0.47	0.71	0.73	0.74	0.57	-0.11	0.95	0.16	0.73	0.74	0.73	0.86	0.71	0.46	-0.65	0.81	-0.71
Total Current Liabilities	0.79	0.99		0.78	0.85	-0.9	-0.87	0.95	0.91	0.51	0.66	0.67	0.79	0.67	-0.06	0.98	0.22	0.78	0.79	0.78	0.92	0.72	0.53	-0.73	0.87	-0.77
Total Stockholder Equity	0.99	0.74	0.78		0.98	-0.89	-0.97	0.81	0.85	0.88	0.12	0.13	0.99	0.76	-0.06	0.8	0.14	1.0	0.99	0.99	0.89	0.34	0.9	-0.92	0.79	-0.91
Net Tangible Assets	0.96	0.81	0.85	0.98		-0.94	-0.96	0.86	0.91	0.77	0.23	0.26	0.97	0.74	-0.12	0.85	0.1	0.98	0.97	0.96	0.93	0.5	0.81	-0.88	0.79	-0.87
Net Debt	-0.91	-0.87	-0.9	-0.89	-0.94		0.92	-0.89	-0.98	-0.62	-0.35	-0.38	-0.91	-0.6	-0.1	-0.87	-0.33	-0.88	-0.91	-0.91	-0.92	-0.61	-0.67	0.78	-0.76	0.79
Retained Earnings	-0.98	-0.81	-0.87	-0.97	-0.96	0.92		-0.91	-0.9	-0.83	-0.24	-0.24	-0.98	-0.79	-0.08	-0.89	-0.3	-0.97	-0.98	-0.98	-0.92	-0.42	-0.87	0.95	-0.89	0.95
Accounts Payable	0.82	0.89	0.95	0.81	0.86	-0.89	-0.91		0.92	0.55	0.53	0.52	0.83	0.8	0.05	0.96	0.3	0.8	0.83	0.81	0.95	0.7	0.62	-0.83	0.94	-0.84
Cash	0.87	0.87	0.91	0.85	0.91	-0.98	-0.9	0.92		0.56	0.37	0.41	0.88	0.64	0.1	0.89	0.34	0.84	0.88	0.87	0.95	0.64	0.62	-0.76	0.78	-0.75
Non Current Assets Total	0.89	0.47	0.51	0.88	0.77	-0.62	-0.83	0.55	0.56		-0.14	-0.15	0.88	0.71	0.08	0.59	0.2	0.89	0.88	0.89	0.63	-0.07	0.97	-0.88	0.66	-0.84
Non Currrent Assets Other	0.11	0.71	0.66	0.12	0.23	-0.35	-0.24	0.53	0.37	-0.14		0.99	0.12	0.21	-0.17	0.62	0.02	0.11	0.12	0.1	0.36	0.81	-0.2	-0.06	0.41	-0.19
Other Assets	0.12	0.73	0.67	0.13	0.26	-0.38	-0.24	0.52	0.41	-0.15	0.99		0.13	0.16	-0.19	0.62	0.0	0.12	0.13	0.11	0.37	0.83	-0.22	-0.04	0.37	-0.16
Cash And Short Term Investments	1.0	0.74	0.79	0.99	0.97	-0.91	-0.98	0.83	0.88	0.88	0.12	0.13		0.75	0.08	0.82	0.28	0.99	1.0	1.0	0.89	0.34	0.9	-0.93	0.79	-0.91
Common Stock Shares Outstanding	0.75	0.57	0.67	0.76	0.74	-0.6	-0.79	0.8	0.64	0.71	0.21	0.16	0.75		-0.08	0.79	0.1	0.77	0.75	0.75	0.82	0.37	0.74	-0.85	0.87	-0.78
Non Current Liabilities Total	0.08	-0.11	-0.06	-0.06	-0.12	-0.1	-0.08	0.05	0.1	0.08	-0.17	-0.19	0.08	-0.08		-0.01	0.96	-0.06	0.08	0.09	-0.06	-0.17	0.09	-0.05	0.0	-0.02
Other Current Assets	0.81	0.95	0.98	0.8	0.85	-0.87	-0.89	0.96	0.89	0.59	0.62	0.62	0.82	0.79	-0.01		0.26	0.8	0.82	0.8	0.93	0.69	0.59	-0.78	0.91	-0.79
Total Liab	0.28	0.16	0.22	0.14	0.1	-0.33	-0.3	0.3	0.34	0.2	0.02	0.0	0.28	0.1	0.96	0.26		0.14	0.28	0.28	0.19	0.04	0.21	-0.24	0.23	-0.22
Net Invested Capital	0.99	0.73	0.78	1.0	0.98	-0.88	-0.97	0.8	0.84	0.89	0.11	0.12	0.99	0.77	-0.06	0.8	0.14		0.99	0.99	0.88	0.32	0.91	-0.93	0.79	-0.91
Total Current Assets	1.0	0.74	0.79	0.99	0.97	-0.91	-0.98	0.83	0.88	0.88	0.12	0.13	1.0	0.75	0.08	0.82	0.28	0.99		1.0	0.88	0.34	0.9	-0.93	0.79	-0.91
Net Working Capital	1.0	0.73	0.78	0.99	0.96	-0.91	-0.98	0.81	0.87	0.89	0.1	0.11	1.0	0.75	0.09	0.8	0.28	0.99	1.0		0.88	0.32	0.91	-0.93	0.78	-0.91
Capital Surpluse	0.88	0.86	0.92	0.89	0.93	-0.92	-0.92	0.95	0.95	0.63	0.36	0.37	0.89	0.82	-0.06	0.93	0.19	0.88	0.88	0.88		0.6	0.69	-0.85	0.89	-0.81
Non Current Liabilities Other	0.33	0.71	0.72	0.34	0.5	-0.61	-0.42	0.7	0.64	-0.07	0.81	0.83	0.34	0.37	-0.17	0.69	0.04	0.32	0.34	0.32	0.6		-0.03	-0.22	0.47	-0.31
Short Long Term Debt Total	0.91	0.46	0.53	0.9	0.81	-0.67	-0.87	0.62	0.62	0.97	-0.2	-0.22	0.9	0.74	0.09	0.59	0.21	0.91	0.9	0.91	0.69	-0.03		-0.94	0.71	-0.9
Property Plant And Equipment Net	-0.93	-0.65	-0.73	-0.92	-0.88	0.78	0.95	-0.83	-0.76	-0.88	-0.06	-0.04	-0.93	-0.85	-0.05	-0.78	-0.24	-0.93	-0.93	-0.93	-0.85	-0.22	-0.94		-0.9	0.97
Net Receivables	0.79	0.81	0.87	0.79	0.79	-0.76	-0.89	0.94	0.78	0.66	0.41	0.37	0.79	0.87	0.0	0.91	0.23	0.79	0.79	0.78	0.89	0.47	0.71	-0.9		-0.89
Capital Lease Obligations	-0.91	-0.71	-0.77	-0.91	-0.87	0.79	0.95	-0.84	-0.75	-0.84	-0.19	-0.16	-0.91	-0.78	-0.02	-0.79	-0.22	-0.91	-0.91	-0.91	-0.81	-0.31	-0.9	0.97	-0.89

Click cells to compare fundamentals

Akero Therapeutics Account Relationship Matchups

Akero Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Other Current Liab	8.4M	9.4M	18.2M	10.8M	11.6M	9.4M
Total Current Liabilities	9.4M	13.1M	25.1M	19.1M	19.1M	13.9M
Total Stockholder Equity	128.7M	258.7M	169.1M	326.6M	535.3M	562.1M
Net Tangible Assets	128.7M	258.7M	169.1M	326.6M	375.5M	394.3M
Net Debt	(136.4M)	(185.4M)	(149.0M)	(238.8M)	(207.9M)	(218.3M)
Retained Earnings	(130.3M)	(209.5M)	(310.3M)	(422.3M)	(574.1M)	(545.4M)
Accounts Payable	947K	3.4M	6.7M	8.0M	7.0M	4.3M
Cash	136.4M	187.2M	150.5M	249.8M	234.2M	162.6M
Non Current Assets Total	69K	2.0M	2.0M	1.4M	20.3M	21.3M
Non Currrent Assets Other	29K	161K	417K	108K	(1.0)	(0.95)
Other Assets	69K	201K	417K	108K	1.0	0.95
Cash And Short Term Investments	136.4M	268.4M	188.3M	351.4M	550.0M	577.5M
Common Stock Shares Outstanding	15.1M	31.5M	34.8M	39.0M	52.6M	34.6M
Short Term Investments	71.6M	81.1M	37.8M	101.7M	315.8M	331.6M
Liabilities And Stockholders Equity	138.1M	273.3M	195.5M	356.6M	580.3M	609.3M
Non Current Liabilities Total	23K	1.5M	1.3M	10.9M	25.8M	19.4M
Other Current Assets	1.6M	5.9M	10.6M	7.4M	10.0M	5.8M
Other Stockholder Equity	120.9M	468.2M	479.4M	748.9M	1.1B	1.2B
Total Liab	9.4M	14.6M	26.4M	30.0M	45.0M	29.5M
Net Invested Capital	128.7M	258.7M	169.1M	336.1M	560.3M	588.3M
Total Current Assets	138.0M	271.3M	193.6M	355.2M	560.0M	588.0M
Accumulated Other Comprehensive Income	(6K)	(3K)	(27K)	37K	270K	283.5K
Net Working Capital	128.7M	258.2M	168.5M	336.1M	540.8M	567.9M
Capital Surpluse	259.0M	468.2M	479.4M	748.9M	861.2M	438.3M

Pair Trading with Akero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Akero Stock

0.76

BMY

Bristol Myers Squibb Aggressive Push

Pair Corr

Moving against Akero Stock

0.8	FDMT	4D Molecular Therapeutics	Pair Corr
0.77	NKTX	Nkarta Inc Buyout Trend	Pair Corr
0.76	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.67	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.66	PEPG	PepGen	Pair Corr

The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.

The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:

How To Invest In Akero

Details

Is Akero Stock a good investment?

Details

What is Akero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.78)

Return On Assets

(0.23)

Return On Equity

(0.36)

The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Akero Total Liab vs Retained Earnings Analysis

Total Liab vs Retained Earnings

Total Liab vs Retained Earnings Correlation Analysis

Correlation Coefficient

Total Liab

Retained Earnings

Akero Therapeutics fundamental ratios Correlations

Akero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Akero Therapeutics fundamental ratios Accounts

Pair Trading with Akero Therapeutics

Moving together with Akero Stock

Moving against Akero Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments

Net Working Capital	- 0.98	Retained Earnings
Total Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings
Cash	- 0.98	Net Debt
Retained Earnings	- 0.98	Total Assets
Net Invested Capital	- 0.97	Retained Earnings